INS VNTR — The Thymic Tolerance Switch
The insulin gene (INS) on chromosome 11p15.5 controls more than blood sugar
regulation. A polymorphic repeat region in its promoter — the
Variable Number Tandem Repeat11 Variable Number Tandem Repeat
A stretch of short DNA sequences repeated
between 26 and ~200 times just upstream of the insulin coding region
(VNTR) — determines how much insulin is expressed in the thymus, the organ that
trains the immune system to ignore the body's own tissues. The rs689 A/T SNP
is a tag variant in near-complete
linkage disequilibrium22 linkage disequilibrium
LD means the A/T allele at rs689 reliably predicts
which VNTR class a person carries, without sequencing the repeat itself
with the VNTR class: the A allele marks the shorter Class I repeats
(26–63 copies), and the T allele marks the longer Class III repeats
(~140–210 copies). This single locus — IDDM2 — accounts for roughly 10% of
the familial clustering of type 1 diabetes (T1D) and is the strongest
non-HLA genetic risk factor for the disease.
The Mechanism
The rs689 A allele weakens the polypyrimidine tract33 polypyrimidine tract
A pyrimidine-rich
sequence just upstream of the intron 1 splice acceptor site that U2AF35
protein must bind to initiate splicing
at the 3′ splice site of INS intron 1. In carriers of the A allele,
intron 1 retention increases and proinsulin output drops — the INS transcript
is less efficiently processed. In
medullary thymic epithelial cells44 medullary thymic epithelial cells
mTECs are the cells that present
self-antigens including insulin to developing T cells; T cells that react
too strongly are deleted — a process called central tolerance
(mTECs), this reduced insulin expression means fewer insulin-reactive
T cells are deleted during immune education.
Cai et al.55 Cai et al.
Cai CQ et al. Both polymorphic VNTR and AIRE modulate
differential expression of insulin in human thymic epithelial cells.
Diabetes, 2010 measured a
threefold difference in thymic insulin mRNA between Class III and Class I
carriers in an AIRE-dependent manner. The surviving auto-reactive T cells
can later reach the pancreas and destroy insulin-producing beta cells.
The Evidence
The most direct evidence comes from
Kralovicova & Vorechovsky66 Kralovicova & Vorechovsky
Kralovicova J, Vorechovsky I. Allele-specific
recognition of the 3′ splice site of INS intron 1. Hum Genet, 2010,
who showed that introducing the A allele into a protective Class III haplotype
was sufficient to reduce proinsulin levels to those of a risk Class I construct.
This positions rs689 — not the VNTR repeat count itself — as the
functional effector77 functional effector
Earlier models assumed the VNTR repeat length was
the causal element; the 2010 work demonstrated the flanking SNPs controlling
splicing are the true functional variants.
Fan et al.88 Fan et al.
Fan Y et al. Thymus-specific deletion of insulin induces
autoimmune diabetes. EMBO J, 2009
deleted insulin expression specifically in mTECs in mice and found 100%
diabetes penetrance within 3 weeks postnatal — the most direct demonstration
that thymic insulin is required for central tolerance to insulin-producing
beta cells.
GWAS evidence is exceptionally strong: the GWAS Catalog records associations with T1D at p = 5 × 10⁻¹⁹⁶ for the A allele. The protective T allele (Class III) carries an OR of approximately 0.45 for T1D (OR ≈ 2.21 per T allele for protection in one large study), with risk frequency of the A allele at ~28% in Europeans. In African populations the A allele is markedly more common (~76%), but HLA alleles dominant in T1D susceptibility are rarer in African-ancestry populations, so the overall T1D rate does not simply track the A allele frequency.
Practical Actions
The INS VNTR locus primarily informs T1D risk stratification, not treatment. There are no approved interventions that modify VNTR function. For AA homozygotes, the main value is awareness: earlier monitoring for T1D-associated autoantibodies (IAA, GADA, IA-2A, ZnT8A) substantially improves the chance of catching pre-symptomatic T1D before diabetic ketoacidosis occurs. At-risk individuals can also evaluate eligibility for T1D prevention trials such as teplizumab (anti-CD3 antibody), which has FDA approval to delay T1D onset in at-risk individuals with 2+ autoantibodies.
Interactions
The IDDM2 effect is additive with HLA class II risk alleles. Individuals carrying both the AA genotype here and high-risk HLA-DR3/DR4-DQ8 haplotypes have substantially higher lifetime T1D risk than either locus predicts alone. rs3842753 (the −23HphI variant, also in the INS 3′ UTR) is a second INS tag SNP in high LD with rs689 and is often co-analyzed. rs7903146 (TCF7L2) primarily affects T2D risk through beta-cell mass, a distinct mechanism from the central tolerance pathway here.